Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Clinical trial NCT03753919 · TERMINATED

Trial details

NCT number: NCT03753919
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Thyroid Papillary Carcinoma Metastatic Thyroid Follicular Carcinoma Metastatic Thyroid Cancer

Start date: 2019-04-02
Primary completion: 2024-11-08
Enrollment: 79

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.